AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
出版年份 2019 全文链接
标题
AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
作者
关键词
-
出版物
Cell Death & Disease
Volume 10, Issue 5, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-05-01
DOI
10.1038/s41419-019-1601-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- (2019) Hirokazu Taniguchi et al. Nature Communications
- Esculetin suppresses tumor growth and metastasis by targeting Axin2/E-cadherin axis in colorectal cancer
- (2018) Won Kyung Kim et al. BIOCHEMICAL PHARMACOLOGY
- Oncogene-Driven Metabolic Alterations in Cancer
- (2018) Hye-Young Min et al. Biomolecules & Therapeutics
- Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
- (2018) Zhe Yang et al. CLINICAL CANCER RESEARCH
- The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer
- (2018) Jane Antony et al. EMBO REPORTS
- Discovery of 2,4,6-trisubstitued pyrido[3,4- d ]pyrimidine derivatives as new EGFR-TKIs
- (2018) Hao Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
- (2018) Shang-Gin Wu et al. Molecular Cancer
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
- (2018) Marie-Anne Goyette et al. Cell Reports
- Moving osimertinib to first-line: the right “strategy” in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?
- (2018) Francesco Passiglia et al. Journal of Thoracic Disease
- Targeting Nicotinamide N -Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells
- (2018) Duc-Hiep Bach et al. Molecular Therapy-Nucleic Acids
- Common Co-activation of AXL and CDCP1 in EGFR -mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis
- (2018) Niki Karachaliou et al. EBioMedicine
- Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation
- (2018) Han Na Kang et al. LUNG CANCER
- BMP4 Upregulation Is Associated with Acquired Drug Resistance and Fatty Acid Metabolism in EGFR-Mutant Non-Small-Cell Lung Cancer Cells
- (2018) Duc-Hiep Bach et al. Molecular Therapy-Nucleic Acids
- Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site
- (2017) Marcel Günther et al. JOURNAL OF MEDICINAL CHEMISTRY
- The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor
- (2017) Toni M. Brand et al. Science Signaling
- Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
- (2017) Kirstine Jacobsen et al. Nature Communications
- The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor
- (2017) Toni M. Brand et al. Science Signaling
- Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia
- (2016) Isabel Ben-Batalla et al. CLINICAL CANCER RESEARCH
- Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies
- (2016) Mihalis S. Kariolis et al. JOURNAL OF CLINICAL INVESTIGATION
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New twists in the AXL(e) of tumor progression
- (2016) B. Halmos et al. Science Signaling
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- Reprogramming the immunological microenvironment through radiation and targeting Axl
- (2016) Todd A. Aguilera et al. Nature Communications
- Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
- (2016) Erik S. Linklater et al. Oncotarget
- Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions
- (2016) Song Yi Bae et al. Scientific Reports
- New twists in the AXL(e) of tumor progression
- (2016) B. Halmos et al. Science Signaling
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
- (2015) Moshe Elkabets et al. CANCER CELL
- Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer
- (2015) Song Yi Bae et al. Oncotarget
- Axl as a mediator of cellular growth and survival
- (2015) Haley Axelrod et al. Oncotarget
- AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
- (2014) C. Wilson et al. CANCER RESEARCH
- AXL Mediates Resistance to Cetuximab Therapy
- (2014) T. M. Brand et al. CANCER RESEARCH
- EGFR Mutations in Asian Patients with Advanced Lung Adenocarcinoma
- (2014) Chong-Kin Liam et al. Journal of Thoracic Oncology
- An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis
- (2014) Mihalis S Kariolis et al. Nature Chemical Biology
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- Anticancer Activity of Novel Daphnane Diterpenoids from Daphne genkwa through Cell-Cycle Arrest and Suppression of Akt/STAT/Src Signalings in Human Lung Cancer Cells
- (2013) Si-Kyoung Jo et al. Biomolecules & Therapeutics
- Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
- (2013) Keith M. Giles et al. MOLECULAR CANCER THERAPEUTICS
- Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival
- (2013) S Ammoun et al. ONCOGENE
- AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells
- (2013) M K Asiedu et al. ONCOGENE
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Daphnane Diterpene Esters with Anti-proliferative Activities against Human Lung Cancer Cells from Daphne genkwa
- (2010) Ji-Young Hong et al. CHEMICAL & PHARMACEUTICAL BULLETIN
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started